UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000050641
Receipt number R000057690
Scientific Title Study on pulmonary parenchymal destruction in bronchial asthma
Date of disclosure of the study information 2023/03/21
Last modified on 2024/03/24 11:31:17

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study on pulmonary parenchymal destruction in bronchial asthma

Acronym

Study on pulmonary parenchymal destruction in bronchial asthma

Scientific Title

Study on pulmonary parenchymal destruction in bronchial asthma

Scientific Title:Acronym

Study on pulmonary parenchymal destruction in bronchial asthma

Region

Japan


Condition

Condition

Study on pulmonary parenchymal destruction in asthma

Classification by specialty

Pneumology Adult

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

To evaluate the parenchymal destruction on preoperative CT in patients with any respiratory disease other than puomonary nodules, non-smokers with asthma, smokers with asthma and chronic obstructive pulmonary disease (COPD) who have undergone lung resection of more than one area due to local lesions such as lung cancer, and to compare pathology (including micro-CT) and molecular biology in the lungs.

Basic objectives2

Others

Basic objectives -Others

biology and molecular biology

Trial characteristics_1

Confirmatory

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

CT pulmonary parenchymal destruction index (Exponent D, low attenuation area percent), pathological index (alveolar space length (mean linear intercept), number of alveolar attachments, number of terminal bronchioles) in resected lung specimens

Key secondary outcomes

Exploratory evaluation using mRNA microarray, Pulmonary elastic fiber-related factors including collagen I, collagen III, fibronectin, matrix metalloproteinase (MMP)-1,MMP-2, MMP-9, tissue inhibitor of metalloproteinase (TIMP)


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

100 years-old >=

Gender

Male and Female

Key inclusion criteria

Patients who have undergone a lung resection of more than one area due to local lesions such as lung cancer between 2006 and November 30, 2021 at the Department of Respiratory Surgery, Hokkaido University Hospital will be eligible for this study.
(1) Patients who have no respiratory disease other than the primary disease of surgery, or who have asthma or COPD as a complication.
(2) Those who have given their free and voluntary consent to participate in this study, or those who have not received any refusal from the research subjects or those who are considered to represent the will and interests of the research subjects with regard to participation in this study.


Translated with DeepL

Key exclusion criteria

1 Those who have a complication of respiratory disease other than the present illness of surgery, asthma, or COPD.
2 Those deemed inappropriate as subjects by the principal investigator

Target sample size

25


Research contact person

Name of lead principal investigator

1st name Kaoruko
Middle name
Last name Shimizu

Organization

Hokkaido University

Division name

Graduate school of medicine, school of medicine, Respiratory Medicine

Zip code

060-8638

Address

West 5, North 15, Kita-ku, Sapporo

TEL

+81117065911

Email

kaorukoshimizu@pop.med.hokudai.ac.jp


Public contact

Name of contact person

1st name Kaoruko
Middle name
Last name Shimizu

Organization

Hokkaido University

Division name

Graduate School of Medicine, School of Medicine, Respiratory Medicine

Zip code

060-8638

Address

West 7, North 15, Kita-ku, Sapporo

TEL

+81117065911

Homepage URL


Email

kaorukoshimizu@pop.med.hokudai.ac.jp


Sponsor or person

Institute

Ministry of Health, Labour and Welfare

Institute

Department

Personal name



Funding Source

Organization

Ministry of Health, Labour and Welfare

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Office of IRB, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital

Address

West 5, North 15, Kita-ku, Sapporo

Tel

011-706-7636

Email

crjimu@huhp.hokudai.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

北海道大学病院


Other administrative information

Date of disclosure of the study information

2023 Year 03 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2022 Year 01 Month 24 Day

Date of IRB

2022 Year 07 Month 17 Day

Anticipated trial start date

2023 Year 08 Month 17 Day

Last follow-up date

2025 Year 03 Month 31 Day

Date of closure to data entry

2026 Year 03 Month 31 Day

Date trial data considered complete

2026 Year 03 Month 31 Day

Date analysis concluded



Other

Other related information

The study will be finalized by the time when the examination on pathological and molecular biology in the participants.


Management information

Registered date

2023 Year 03 Month 21 Day

Last modified on

2024 Year 03 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000057690


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name